Alexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Earnings of $2.35 Per Share

Wall Street analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post earnings per share (EPS) of $2.35 for the current quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The lowest EPS estimate is $2.23 and the highest is $2.51. Alexion Pharmaceuticals reported earnings of $2.07 per share in the same quarter last year, which would indicate a positive year over year growth rate of 13.5%. The firm is expected to report its next earnings report on Thursday, July 25th.

On average, analysts expect that Alexion Pharmaceuticals will report full-year earnings of $9.50 per share for the current year, with EPS estimates ranging from $9.31 to $9.97. For the next financial year, analysts anticipate that the business will report earnings of $10.50 per share, with EPS estimates ranging from $8.93 to $12.22. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.40. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The company’s revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.68 earnings per share.

A number of research analysts have weighed in on ALXN shares. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. Guggenheim reiterated a “neutral” rating and issued a $135.00 price objective on shares of Alexion Pharmaceuticals in a research report on Thursday, March 21st. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Cowen reiterated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 13th. Finally, Morgan Stanley upped their price target on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $161.06.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker sold 123,489 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $126.53, for a total transaction of $15,625,063.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.08% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the business. Investors Research Corp bought a new position in Alexion Pharmaceuticals in the 1st quarter valued at about $27,000. Captrust Financial Advisors purchased a new stake in Alexion Pharmaceuticals during the fourth quarter valued at about $31,000. Berman Capital Advisors LLC lifted its stake in Alexion Pharmaceuticals by 68.6% during the first quarter. Berman Capital Advisors LLC now owns 322 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 131 shares in the last quarter. Institutional & Family Asset Management LLC lifted its stake in Alexion Pharmaceuticals by 39.5% during the first quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 87 shares in the last quarter. Finally, Kaizen Advisory LLC lifted its stake in Alexion Pharmaceuticals by 22.2% during the fourth quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 111 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors.

Shares of Alexion Pharmaceuticals stock opened at $118.78 on Monday. The stock has a market capitalization of $26.36 billion, a price-to-earnings ratio of 16.75, a PEG ratio of 0.92 and a beta of 1.58. Alexion Pharmaceuticals has a fifty-two week low of $92.56 and a fifty-two week high of $141.86. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.87 and a quick ratio of 3.36.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: What is a trade deficit?

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.